Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients

Patients with kidney failure who require hemodialysis often suffer from anemia (low red blood cell count), heart and blood vessel problems, and a condition involving poor nutrition, inflammation, and hardening of the arteries (called MIA syndrome). Standard treatments for anemia often involve injections and iron supplements. This study aims to see if a newer oral medication, Roxadustat, works better than these standard treatments not only for anemia but also for improving cardiovascular health and the MIA syndrome. Participants in the study will be randomly assigned (like by chance) to one of two groups. One group will receive Roxadustat, while the other group will continue with their conventional anemia treatment. Researchers will compare the effects on heart function, markers of nutrition and inflammation, and anemia levels in both groups over a 6-month period.

NCT Number	NCT06903559
Lead Sponsor	Mansoura University
Conditions	Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease, Cardiovascular Diseases (CVD)
Enrollment	46 participants
Start Date	2025-04-15
Primary Completion	2025-10-15 (estimated)
Study Completion	2025-11-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-13